Medios AG (ILM1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medios AG (ILM1) has a cash flow conversion efficiency ratio of 0.021x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.96 Million ≈ $12.81 Million USD) by net assets (€519.70 Million ≈ $607.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Medios AG balance sheet quality to measure how much of total assets are equity-financed.
Medios AG - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Medios AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Medios AG earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Medios AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medios AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G Willi-Food International Ltd
TA:WILC
|
0.034x |
|
Bhansali Engineering Polymers Limited
NSE:BEPL
|
0.036x |
|
Oponeo.pl SA
WAR:OPN
|
-0.042x |
|
Precious Shipping Public Company Limited
BK:PSL-R
|
0.038x |
|
FSP Technology Inc
TW:3015
|
-0.011x |
|
Perpetual Credit Income Trust
AU:PCI
|
-0.079x |
|
Nano Dimension Ltd
NASDAQ:NNDM
|
-0.020x |
|
Zhejiang Double Arrow Rubber Co Ltd
SHE:002381
|
0.067x |
Annual Cash Flow Conversion Efficiency for Medios AG (2010–2025)
The table below shows the annual cash flow conversion efficiency of Medios AG from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see Medios AG market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €514.22 Million ≈ $601.18 Million |
€43.00 Million ≈ $50.27 Million |
0.084x | -42.08% |
| 2024-12-31 | €510.19 Million ≈ $596.47 Million |
€73.67 Million ≈ $86.12 Million |
0.144x | +312.59% |
| 2023-12-31 | €468.81 Million ≈ $548.08 Million |
€16.41 Million ≈ $19.18 Million |
0.035x | -57.76% |
| 2022-12-31 | €448.05 Million ≈ $523.81 Million |
€37.12 Million ≈ $43.40 Million |
0.083x | -46.92% |
| 2021-12-31 | €394.16 Million ≈ $460.82 Million |
€61.52 Million ≈ $71.92 Million |
0.156x | +158.32% |
| 2020-12-31 | €142.43 Million ≈ $166.51 Million |
€-38.12 Million ≈ $-44.56 Million |
-0.268x | -4762.04% |
| 2019-12-31 | €81.63 Million ≈ $95.43 Million |
€-449.29K ≈ $-525.26K |
-0.006x | +87.62% |
| 2018-12-31 | €70.50 Million ≈ $82.42 Million |
€-3.14 Million ≈ $-3.67 Million |
-0.044x | -348.97% |
| 2017-12-31 | €45.68 Million ≈ $53.40 Million |
€816.00K ≈ $953.99K |
0.018x | +138.51% |
| 2016-12-31 | €34.10 Million ≈ $39.86 Million |
€-1.58 Million ≈ $-1.85 Million |
-0.046x | +84.92% |
| 2015-12-31 | €323.78K ≈ $378.53K |
€-99.64K ≈ $-116.49K |
-0.308x | -- |
| 2014-12-31 | €0.00 ≈ $0.00 |
€13.30K ≈ $15.55K |
x | -- |
| 2013-12-31 | €7.81K ≈ $9.13K |
€103.36K ≈ $120.84K |
13.241x | +10691.51% |
| 2012-12-31 | €172.97K ≈ $202.22K |
€21.22K ≈ $24.81K |
0.123x | +157.35% |
| 2011-12-31 | €376.75K ≈ $440.46K |
€-80.60K ≈ $-94.23K |
-0.214x | -1872.06% |
| 2010-12-31 | €341.07K ≈ $398.75K |
€-3.70K ≈ $-4.33K |
-0.011x | -- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more